Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 750 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher

Dr. Leiter is a past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Distinguished Service Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.  In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences

Recent Publications

  1. Pieber, TR, Bajaj, HS, Heller, SR, Jia, T, Khunti, K, Klonoff, DC et al.. Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial. Diabetes Obes Metab. 2021; :. doi: 10.1111/dom.14564. PubMed PMID:34605127 .
  2. Myna, R, Hellmayr, R, Georgiades, M, Leiter, LM, Frömel-Frybort, S, Wimmer, R et al.. Can Surface Coating of Circular Saw Blades Potentially Reduce Dust Formation?. Materials (Basel). 2021;14 (18):. doi: 10.3390/ma14185123. PubMed PMID:34576349 PubMed Central PMC8469391.
  3. Berg, DD, Wiviott, SD, Scirica, BM, Zelniker, TA, Goodrich, EL, Jarolim, P et al.. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care. 2021; :. doi: 10.2337/dc21-1170. PubMed PMID:34535469 .
  4. Kosmopoulos, A, Bhatt, DL, Meglis, G, Verma, R, Pan, Y, Quan, A et al.. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. iScience. 2021;24 (9):103040. doi: 10.1016/j.isci.2021.103040. PubMed PMID:34462732 PubMed Central PMC8388138.
  5. Batra, G, Ghukasyan Lakic, T, Lindbäck, J, Held, C, White, HD, Stewart, RAH et al.. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol. 2021; :. doi: 10.1001/jamacardio.2021.3079. PubMed PMID:34431970 PubMed Central PMC8387946.
  6. Oyama, K, Raz, I, Cahn, A, Kuder, J, Murphy, SA, Bhatt, DL et al.. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J. 2021; :. doi: 10.1093/eurheartj/ehab530. PubMed PMID:34427295 .
  7. Lo, S, Leiter, LA, Langer, A, Tan, M, Goldin, L, Harris, S et al.. Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. J Diabetes Complications. 2021;35 (10):107997. doi: 10.1016/j.jdiacomp.2021.107997. PubMed PMID:34332851 .
  8. Langer, A, Mancini, GBJ, Tan, M, Goodman, SG, Ahooja, V, Grégoire, J et al.. Treatment Inertia in Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021;10 (14):e020126. doi: 10.1161/JAHA.120.020126. PubMed PMID:34238023 PubMed Central PMC8483494.
  9. Mosenzon, O, Wiviott, SD, Heerspink, HJL, Dwyer, JP, Cahn, A, Goodrich, EL et al.. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021;44 (8):1805-1815. doi: 10.2337/dc21-0076. PubMed PMID:34233928 PubMed Central PMC8385472.
  10. Sharma, A, Aziz, H, Verma, S, Abramson, BL, Choi, R, Chua, GL et al.. Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. Curr Opin Cardiol. 2021;36 (5):672-681. doi: 10.1097/HCO.0000000000000892. PubMed PMID:34173772 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto
X